ong-term follow-up of patients previously treated with an Autolus CAR T cell therapy
Phase 1
- Conditions
- Potential malignancy in patients who received treatment with Autolus' CAR T cell therapy.Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2016-004867-38-NL
- Lead Sponsor
- Autolus Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
•Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
•Patients must have provided informed consent for long-term follow-up study prior to participation.
•Patients must be able to comply with the study requirements.
Are the trial subjects under 18? yes
Number of subjects for this age range: 39
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 169
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 292
Exclusion Criteria
- There are no specific exclusion criteria for this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method